Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0RD4F)

• Drug Name: DS-6051 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 72202474
  TTD Drug ID: DM0RD4F

Molecule-Related Drug Atlas

Drug(s) Targeting Tropomyosin-related kinase A (TrkA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[3]
Repotrectinib	DM9FB2T	Non-small-cell lung cancer	2C25	Approved	[4]
Larotrectinib	DM26CQR	Solid tumour/cancer	2A00-2F9Z	Approved	[5]
MIM-D3	DMZHN5B	Alzheimer disease	8A20	Phase 3	[6]
SNA-120	DMPN314	Plaque psoriasis	EA90.0	Phase 2	[7]
CT 327	DMQXL1T	Plaque psoriasis	EA90.0	Phase 2	[8]
ONO-7579	DMXLPYE	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[10]
LOXO-195	DMDXFBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]

Drug(s) Targeting Proto-oncogene c-Ros (ROS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[11]
Lorlatinib	DMICDLV	Non-small-cell lung cancer	2C25.Y	Approved	[5]
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[3]
Repotrectinib	DM9FB2T	Non-small-cell lung cancer	2C25	Approved	[4]
AB-106	DMEW62S	Non-small-cell lung cancer	2C25	Phase 2	[12]
Carboxamide derivative 4	DMU5GKC	N. A.	N. A.	Patented	[13]
Imidazo[1,2-b]pyridazine derivative 2	DM1JYNW	Solid tumour/cancer	2A00-2F9Z	Patented	[9]
Imidazo[1,2-b]pyridazine derivative 3	DMPDTG0	Solid tumour/cancer	2A00-2F9Z	Patented	[9]
PMID28270010-Compound-Figure21-b	DM6IYAT	Brain metastases	2D50	Patented	[9]
Imidazo[1,2-b]pyridazine derivative 1	DMULTAI	Solid tumour/cancer	2A00-2F9Z	Patented	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-Ros (ROS1)	TTSZ6Y3	ROS1_HUMAN	Inhibitor	[2]
Tropomyosin-related kinase A (TrkA)	TTTDVOJ	NTRK1_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT02279433) A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b. U.S. National Institutes of Health.
• [2] National Cancer Institute Drug Dictionary (drug id 766123).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [6] Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
• [9] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [10] National Cancer Institute Drug Dictionary (drug id 747694).
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [12] Clinical pipeline report, company report or official report of AnHeart Therapeutics.
• [13] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.